It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The rapid global spread of the novel coronavirus SARS-CoV-2 has strained healthcare and testing resources, making the identification and prioritization of individuals most at-risk a critical challenge. Recent evidence suggests blood type may affect risk of severe COVID-19. Here, we use observational healthcare data on 14,112 individuals tested for SARS-CoV-2 with known blood type in the New York Presbyterian (NYP) hospital system to assess the association between ABO and Rh blood types and infection, intubation, and death. We find slightly increased infection prevalence among non-O types. Risk of intubation was decreased among A and increased among AB and B types, compared with type O, while risk of death was increased for type AB and decreased for types A and B. We estimate Rh-negative blood type to have a protective effect for all three outcomes. Our results add to the growing body of evidence suggesting blood type may play a role in COVID-19.
Recent evidence has suggested that blood type may be associated with severe COVID-19. Here, the authors use data from ~14,000 individuals tested for SARS-CoV-2 at a New York City hospital, and find that certain ABO and Rh blood types are associated with infection, intubation, and death.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Zucker, Jason 2 ; Tatonetti, Nicholas P 3
1 Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
2 Columbia University Irving Medical Center, Department of Medicine, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
3 Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Columbia University Irving Medical Center, Department of Medicine, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Columbia University Irving Medical Center, Department of Systems Biology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Columbia University Irving Medical Center, Institute for Genomic Medicine, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)




